Cite
Beca JM, Dai WF, Pataky RE, et al. Real-world Safety of Bevacizumab with First-line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer: Population-based Retrospective Cohort Studies in Three Canadian Provinces. Clin Oncol (R Coll Radiol). 2021;34(1):e7-e17doi: 10.1016/j.clon.2021.08.009.
Beca, J. M., Dai, W. F., Pataky, R. E., Tran, D., Dvorani, E., Isaranuwatchai, W., Peacock, S., Alvi, R., Cheung, W. Y., Earle, C. C., Gavura, S., & Chan, K. K. W. (2022). Real-world Safety of Bevacizumab with First-line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer: Population-based Retrospective Cohort Studies in Three Canadian Provinces. Clinical oncology (Royal College of Radiologists (Great Britain)), 34(1), e7-e17. https://doi.org/10.1016/j.clon.2021.08.009
Beca, J M, et al. "Real-world Safety of Bevacizumab with First-line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer: Population-based Retrospective Cohort Studies in Three Canadian Provinces." Clinical oncology (Royal College of Radiologists (Great Britain)) vol. 34,1 (2022): e7-e17. doi: https://doi.org/10.1016/j.clon.2021.08.009
Beca JM, Dai WF, Pataky RE, Tran D, Dvorani E, Isaranuwatchai W, Peacock S, Alvi R, Cheung WY, Earle CC, Gavura S, Chan KKW. Real-world Safety of Bevacizumab with First-line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer: Population-based Retrospective Cohort Studies in Three Canadian Provinces. Clin Oncol (R Coll Radiol). 2022 Jan;34(1):e7-e17. doi: 10.1016/j.clon.2021.08.009. Epub 2021 Aug 26. PMID: 34456106.
Copy
Download .nbib